{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:55:23Z","timestamp":1783054523953,"version":"3.54.6"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102437","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:26:08Z","timestamp":1758086768000},"page":"102437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive Evaluation of Androgen Receptor Pathway Inhibitors in Metastatic Castration-Sensitive Prostate Cancer: A Multicenter Inverse Probability of Treatment Weighting-Based Study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9279-3156","authenticated-orcid":false,"given":"Keita","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6703-9268","authenticated-orcid":false,"given":"Takanori","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8031-4634","authenticated-orcid":false,"given":"Koki","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Sakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shirataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Tei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Tabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0517-8528","authenticated-orcid":false,"given":"Satoru","family":"Yoshihiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chietaka","family":"Ohmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6386-2313","authenticated-orcid":false,"given":"Jumpei","family":"Akao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102437_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102437_bib0002","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102437_bib0003","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102437_bib0004","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with Enzalutamide or Placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102437_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102437_bib0006","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102437_bib0007","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/pros.24813","article-title":"Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: a multicenter study","volume":"85","author":"Yanagisawa","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2025.102437_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102140","article-title":"Clinical outcomes and risk stratification in patients with metastatic hormone-sensitive prostate cancer treated with new-generation androgen receptor signaling inhibitors","volume":"22","author":"Suzuki","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2025.102437_bib0009","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.euo.2024.03.001","article-title":"Three- and seven-month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone-sensitive prostate cancer: results from SWOG S1216, a phase 3 randomized trial of androgen deprivation plus Orteronel or Bicalutamide","volume":"7","author":"Parikh","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102437_bib0010","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/pros.24847","article-title":"Rapid and deep prostate-specific antigen decline is a prognostic marker in metastatic hormone-sensitive prostate cancer: a real-world multi-intuitional analysis","volume":"85","author":"Suzuki","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2025.102437_bib0011","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41391-023-00696-w","article-title":"Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors","volume":"27","author":"Gebrael","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2025.102437_bib0012","article-title":"Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)","author":"Maughan","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2025.102437_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-93136-9","article-title":"The impact of androgen receptor pathway inhibitors as starting treatment in metastatic castration-sensitive prostate cancer on patient outcomes (OASIS Japan)","volume":"15","author":"Shiota","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2025.102437_bib0014","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102437_bib0015","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1007\/s10147-022-02183-z","article-title":"Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium","volume":"27","author":"Tohi","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102437_bib0016","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12894-020-00689-0","article-title":"Skin rash following administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study","volume":"20","author":"Uemura","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.clgc.2025.102437_bib0017","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102437_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.09.009","article-title":"Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial","volume":"6","author":"Bian","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.clgc.2025.102437_bib0019","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.euo.2024.03.001","article-title":"Three- and seven-month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone-sensitive prostate cancer: results from SWOG S1216, a phase 3 randomized trial of androgen deprivation plus Orteronel or Bicalutamide","volume":"7","author":"Parikh","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2025.102437_bib0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102437_bib0021","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/pros.24847","article-title":"Rapid and deep prostate-specific antigen decline is a prognostic marker in metastatic hormone-sensitive prostate cancer: a real-world multi-intuitional analysis","volume":"85","author":"Suzuki","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2025.102437_bib0022","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, cross-over trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102437_bib0023","year":"2025","journal-title":"Prostate Cancer. Version 2"},{"key":"10.1016\/j.clgc.2025.102437_bib0024","unstructured":"EAU Guidelines. Prostate Cancer. 2024 edition. https:\/\/uroweb.org\/guidelines\/prostate-cancer. Accessed June 30, 2025."},{"key":"10.1016\/j.clgc.2025.102437_bib0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00345-024-05388-1","article-title":"Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer","volume":"43","author":"Wenzel","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2025.102437_bib0026","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/pros.24488","article-title":"Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy","volume":"83","author":"Yanagisawa","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2025.102437_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.05.037","article-title":"Postprogression survival of patients with metastatic hormone-sensitive prostate cancer who received Darolutamide or Placebo in combination with docetaxel and androgen deprivation therapy: post hoc analysis of the phase 3 ARASENS trial","author":"Grimm","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102437_bib0028","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2014.11.033","article-title":"Targeting the androgen receptor confers In vivo cross-resistance between Enzalutamide and Docetaxel, but not Cabazitaxel, in castration-resistant prostate cancer","volume":"67","author":"van Soest","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102437_bib0029","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102437_bib0030","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162148","article-title":"Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models","volume":"133","author":"Agarwal","year":"2023","journal-title":"J Clin Invest"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:09:46Z","timestamp":1770671386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1558767325001375"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102437","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Evaluation of Androgen Receptor Pathway Inhibitors in Metastatic Castration-Sensitive Prostate Cancer: A Multicenter Inverse Probability of Treatment Weighting-Based Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102437"}}